Antibody response after the third dose of Covid-19 booster vaccination in healthcare workers.
Keywords:
KEYWORDS: Antibody, Covid-19 booster vaccination, healthcare worker
Abstract
OBJECTIVE
To estimate antibody responses of the anti—S—RBD IgG level after the third dose of Covid—19 booster vaccination in a healthcare worker who completed the primary vaccination course.
METHODS
A prospective cohort single-center study was performed at Chiangrai Prachanukroh Hospital, Thailand to assess the antibody response of healthcare workers who completed the first vaccination course with CoronaVac and boosted third doses of the Covid—19 vaccination with Oxford—AstraZeneca or Pfizer—BioNTech Covid—19 vaccine. Healthcare workers who received the third dose of Covid—19 booster vaccination between August 2021 and October 2021 were asked to enroll in the present study. The anti—S—RBD IgG levels were measured two months after the boosted third dose of the Covid—19 vaccination. The primary outcome was the anti—S—RBD IgG levels after vaccination within two months.
RESULTS
A total of 754 healthcare workers participated in the study; 286 was in the Oxford—AstraZeneca vaccine and 468 in the Pfizer—BioNTech vaccine group . Mostly they were female with age more than 40 years old. the anti S—RBD IgG level level in the Oxford—AstraZeneca group was lower than that of the Pfizer—BioNTech group (median, 5.2x103 AU/ml (IQR 3.3 to 8.0) vs. median, 8.7x103 AU/ml (IQR, 6.0 to 12.3); P<0.001). The pattern pattern in which the the anti S—RBD IgG level level was lower in former groups than that of in the later groups was also observed subgroup of age ≤40 years (P<0.001), age>40 years (P<0.001), female sex (P<0.001), male sex (P<0.001), BMI≤25 kg/m2 (P<0.001), and BMI>25 kg/m2 (P<0.001).
CONCLUSION
The healthcare workers who completed the two-dose primary vaccination course in the Oxford—AstraZeneca group developed lower antibodies after the third dose of Covid—19 booster vaccination than that of the Pfizer— BioNTech group.
References
REFERENCE.
1. Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020;56(2):106054-.
2. Al-Qahtani AA. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Emergence, history, basic and clinical aspects. Saudi Journal of Biological Sciences. 2020;27(10):2531-8.
3. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181-92.
4. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2022, StatPearls Publishing LLC.; 2022.
5. Pang NY-L, Pang AS-R, Chow VT, Wang D-Y. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Military Medical Research. 2021;8(1):47.
6. Yang Y, Yang M, Peng Y, Liang Y, Wei J, Xing L, et al. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nature Microbiology. 2022;7(3):423-33.
7. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. New England Journal of Medicine. 2022.
8. Altawalah H. Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Vaccines (Basel). 2021;9(8):910.
9. Demonbreun AR, Sancilio A, Velez MP, Ryan DT, Saber R, Vaught LA, et al. Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. EClinicalMedicine. 2021;38:101018.
10. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021;326(1):35-45.
11. Bates Timothy A, McBride Savannah K, Leier Hans C, Guzman G, Lyski Zoe L, Schoen D, et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Science Immunology.7(68):eabn8014.
12. Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022.
13. Patel J, Patel P, Akinmuyiwa V. COVID-19 Vaccine Development: Insights, Prospects and Challenges. 2020;1:14-20.
14. Kaplan Robert M, Milstein A. Influence of a COVID-19 vaccine’s effectiveness and safety profile on vaccination acceptance. Proceedings of the National Academy of Sciences. 2021;118(10):e2021726118.
15. Prasithsirikul W, Pongpirul K, Nopsopon T, Phutrakool P, Pongpirul W, Samuthpongtorn C, et al. Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers. Vaccines (Basel). 2022;10(2).
16. Benjamanukul S, Traiyan S, Yorsaeng R, Vichaiwattana P, Sudhinaraset N, Wanlapakorn N, et al. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers. Journal of Medical Virology. 2022;94(4):1442-9.
17. Palacios R, Patiño EG, de Oliveira Piorelli R, Conde MTRP, Batista AP, Zeng G, et al. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):853.
18. Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Frontiers in Immunology. 2020;11.
19. Zhang M-X, Zhang T-T, Shi G-F, Cheng F-M, Zheng Y-M, Tung T-H, et al. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Review of Vaccines. 2021;20(7):891-8.
20. Yavuz E, Günal Ö, Başbulut E, Şen A. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine. Journal of Medical Virology. 2022;n/a(n/a).
21. Tung T-H, Lin X-Q, Chen Y, Zhang M-X, Zhu J-S. Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China. Expert Review of Vaccines. 2022;21(2):261-7.
22. Balkan İİ, Dinc HO, Can G, Karaali R, Ozbey D, Caglar B, et al. Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required. Irish Journal of Medical Science (1971 -). 2022.
23. Yan MZ, Yang M, Lai C-L. Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It. Frontiers in Drug Discovery. 2022;2.
24. Sharma K, Koirala A, Nicolopoulos K, Chiu C, Wood N, Britton PN. Vaccines for COVID-19: Where do we stand in 2021? Paediatric Respiratory Reviews. 2021;39:22-31.
25. Eroglu B, Nuwarda RF, Ramzan I, Kayser V. A Narrative Review of COVID-19 Vaccines. Vaccines (Basel). 2022;10(1).
26. Loo K-Y, Letchumanan V, Ser H-L, Teoh SL, Law JW-F, Tan LT-H, et al. COVID-19: Insights into Potential Vaccines. Microorganisms. 2021;9(3):605.
27. Zhuang C, Liu X, Chen Q, Sun Y, Su Y, Huang S, et al. Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective. Front Microbiol. 2022;13:828806-.
28. Prasithsirikul W, Pongpirul K, Nopsopon T, Phutrakool P, Pongpirul W, Samuthpongtorn C, et al. Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers. Vaccines (Basel). 2022;10(2):217.
29. Padoan A, Cosma C, Bonfante F, Rocca Fd, Barbaro F, Santarossa C, et al. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays. Clinical Chemistry and Laboratory Medicine (CCLM). 2022;60(3):456-63.
30. Abdulla ZA, Al-Bashir SM, Al-Salih NS, Aldamen AA, Abdulazeez MZ. A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development. Pathogens. 2021;10(7):788.
31. Rego GN, Nucci MP, Alves AH, Oliveira FA, Marti LC, Nucci LP, et al. Current clinical trials protocols and the global effort for immunization against SARS-CoV-2. Vaccines (Basel). 2020;8(3):474.
32. Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. British Medical Journal Publishing Group; 2021.
33. Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts. Journal of medical virology. 2022;94(4):1294-9.
34. Ghiasi N, Valizadeh R, Arabsorkhi M, Hoseyni TS, Esfandiari K, Sadighpour T, et al. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion. Immunopathol Persa. 2021;7:31.
35. Mbaeyi S, Oliver SE, Collins JP, Godfrey M, Goswami ND, Hadler SC, et al. The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines—United States, 2021. Morbidity and Mortality Weekly Report. 2021;70(44):1545.
36. Hause AM, Baggs J, Marquez P, Abara WE, Olubajo B, Myers TR, et al. Safety monitoring of COVID-19 Vaccine booster doses among persons aged 12–17 years—United States, December 9, 2021–February 20, 2022. Morbidity and Mortality Weekly Report. 2022;71(9):347.
37. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March–August 2021. Morbidity and Mortality Weekly Report. 2021;70(38):1337.
38. English E, Cook LE, Piec I, Dervisevic S, Fraser WD, John WG. Performance of the Abbott SARS-CoV-2 IgG II quantitative antibody assay including the new variants of concern, VOC 202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and first steps towards global harmonization of COVID-19 antibody methods. Journal of clinical microbiology. 2021;59(9):e00288-21.
39. Manalac J, Yee J, Calayag K, Nguyen L, Patel PM, Zhou D, et al. Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmun ELISA IgG/IgA assays in a clinical lab. Clinica chimica acta. 2020;510:687-90.
40. Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, et al. Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays. Microbiology Spectrum. 2021;9(1):e00247-21.
41. Ortiz-Dosal A, Loredo-García E, Álvarez-Contreras AG, Núñez-Leyva JM, Ortiz-Dosal LC, Kolosovas-Machuca ES. Determination of the Immunoglobulin G Spectrum by Surface-Enhanced Raman Spectroscopy Using Quasispherical Gold Nanoparticles. Journal of Nanomaterials. 2021;2021.
42. Initiative C-HG. The COVID-19 host genetics initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. European Journal of Human Genetics. 2020;28(6):715.
43. Velikova T, Georgiev T. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatology international. 2021;41(3):509-18.
44. Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Science of the Total Environment. 2020;730:138996.
45. Lee SW, Moon J-Y, Lee S-K, Lee H, Moon S, Chung SJ, et al. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions. Frontiers in immunology. 2021;12:779212-.
46. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight US locations, December 2020–March 2021. Morbidity and Mortality Weekly Report. 2021;70(13):495.
47. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nature Reviews Immunology. 2021;21(10):626-36.
48. Sultana J, Mazzaglia G, Luxi N, Cancellieri A, Capuano A, Ferrajolo C, et al. Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. Expert review of vaccines. 2020;19(10):919-36.
49. Eyre DW, Lumley SF, Wei J, Cox S, James T, Justice A, et al. Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status. Clinical Microbiology and Infection. 2021;27(10):1516. e7-. e14.
50. Whitaker HJ, Tsang RSM, Byford R, Andrews NJ, Sherlock J, Sebastian Pillai P, et al. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. J Infect. 2022;84(5):675-83.
51. Kaura A, Trickey A, Shah AS, Benedetto U, Glampson B, Mulla A, et al. Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum. EClinicalMedicine. 2022;46:101344.
52. Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. bmj. 2021;373.
53. Ranzani OT, Hitchings MD, Dorion M, D’Agostini TL, de Paula RC, de Paula OFP, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. bmj. 2021;374.
54. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. bmj. 2022;376.
55. Cucunawangsih C, Wijaya RS, Lugito NPH, Suriapranata I. Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine. Int J Infect Dis. 2022;118:116-8.
56. Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: A review. Vaccine. 2018;36(36):5350-7.
57. Kaura A, Trickey A, Shah ASV, Benedetto U, Glampson B, Mulla A, et al. Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum. eClinicalMedicine. 2022;46:101344.
1. Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020;56(2):106054-.
2. Al-Qahtani AA. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Emergence, history, basic and clinical aspects. Saudi Journal of Biological Sciences. 2020;27(10):2531-8.
3. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181-92.
4. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2022, StatPearls Publishing LLC.; 2022.
5. Pang NY-L, Pang AS-R, Chow VT, Wang D-Y. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Military Medical Research. 2021;8(1):47.
6. Yang Y, Yang M, Peng Y, Liang Y, Wei J, Xing L, et al. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nature Microbiology. 2022;7(3):423-33.
7. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. New England Journal of Medicine. 2022.
8. Altawalah H. Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Vaccines (Basel). 2021;9(8):910.
9. Demonbreun AR, Sancilio A, Velez MP, Ryan DT, Saber R, Vaught LA, et al. Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. EClinicalMedicine. 2021;38:101018.
10. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021;326(1):35-45.
11. Bates Timothy A, McBride Savannah K, Leier Hans C, Guzman G, Lyski Zoe L, Schoen D, et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Science Immunology.7(68):eabn8014.
12. Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022.
13. Patel J, Patel P, Akinmuyiwa V. COVID-19 Vaccine Development: Insights, Prospects and Challenges. 2020;1:14-20.
14. Kaplan Robert M, Milstein A. Influence of a COVID-19 vaccine’s effectiveness and safety profile on vaccination acceptance. Proceedings of the National Academy of Sciences. 2021;118(10):e2021726118.
15. Prasithsirikul W, Pongpirul K, Nopsopon T, Phutrakool P, Pongpirul W, Samuthpongtorn C, et al. Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers. Vaccines (Basel). 2022;10(2).
16. Benjamanukul S, Traiyan S, Yorsaeng R, Vichaiwattana P, Sudhinaraset N, Wanlapakorn N, et al. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers. Journal of Medical Virology. 2022;94(4):1442-9.
17. Palacios R, Patiño EG, de Oliveira Piorelli R, Conde MTRP, Batista AP, Zeng G, et al. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):853.
18. Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Frontiers in Immunology. 2020;11.
19. Zhang M-X, Zhang T-T, Shi G-F, Cheng F-M, Zheng Y-M, Tung T-H, et al. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Review of Vaccines. 2021;20(7):891-8.
20. Yavuz E, Günal Ö, Başbulut E, Şen A. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine. Journal of Medical Virology. 2022;n/a(n/a).
21. Tung T-H, Lin X-Q, Chen Y, Zhang M-X, Zhu J-S. Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China. Expert Review of Vaccines. 2022;21(2):261-7.
22. Balkan İİ, Dinc HO, Can G, Karaali R, Ozbey D, Caglar B, et al. Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required. Irish Journal of Medical Science (1971 -). 2022.
23. Yan MZ, Yang M, Lai C-L. Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It. Frontiers in Drug Discovery. 2022;2.
24. Sharma K, Koirala A, Nicolopoulos K, Chiu C, Wood N, Britton PN. Vaccines for COVID-19: Where do we stand in 2021? Paediatric Respiratory Reviews. 2021;39:22-31.
25. Eroglu B, Nuwarda RF, Ramzan I, Kayser V. A Narrative Review of COVID-19 Vaccines. Vaccines (Basel). 2022;10(1).
26. Loo K-Y, Letchumanan V, Ser H-L, Teoh SL, Law JW-F, Tan LT-H, et al. COVID-19: Insights into Potential Vaccines. Microorganisms. 2021;9(3):605.
27. Zhuang C, Liu X, Chen Q, Sun Y, Su Y, Huang S, et al. Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective. Front Microbiol. 2022;13:828806-.
28. Prasithsirikul W, Pongpirul K, Nopsopon T, Phutrakool P, Pongpirul W, Samuthpongtorn C, et al. Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers. Vaccines (Basel). 2022;10(2):217.
29. Padoan A, Cosma C, Bonfante F, Rocca Fd, Barbaro F, Santarossa C, et al. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays. Clinical Chemistry and Laboratory Medicine (CCLM). 2022;60(3):456-63.
30. Abdulla ZA, Al-Bashir SM, Al-Salih NS, Aldamen AA, Abdulazeez MZ. A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development. Pathogens. 2021;10(7):788.
31. Rego GN, Nucci MP, Alves AH, Oliveira FA, Marti LC, Nucci LP, et al. Current clinical trials protocols and the global effort for immunization against SARS-CoV-2. Vaccines (Basel). 2020;8(3):474.
32. Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. British Medical Journal Publishing Group; 2021.
33. Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts. Journal of medical virology. 2022;94(4):1294-9.
34. Ghiasi N, Valizadeh R, Arabsorkhi M, Hoseyni TS, Esfandiari K, Sadighpour T, et al. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion. Immunopathol Persa. 2021;7:31.
35. Mbaeyi S, Oliver SE, Collins JP, Godfrey M, Goswami ND, Hadler SC, et al. The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines—United States, 2021. Morbidity and Mortality Weekly Report. 2021;70(44):1545.
36. Hause AM, Baggs J, Marquez P, Abara WE, Olubajo B, Myers TR, et al. Safety monitoring of COVID-19 Vaccine booster doses among persons aged 12–17 years—United States, December 9, 2021–February 20, 2022. Morbidity and Mortality Weekly Report. 2022;71(9):347.
37. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March–August 2021. Morbidity and Mortality Weekly Report. 2021;70(38):1337.
38. English E, Cook LE, Piec I, Dervisevic S, Fraser WD, John WG. Performance of the Abbott SARS-CoV-2 IgG II quantitative antibody assay including the new variants of concern, VOC 202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and first steps towards global harmonization of COVID-19 antibody methods. Journal of clinical microbiology. 2021;59(9):e00288-21.
39. Manalac J, Yee J, Calayag K, Nguyen L, Patel PM, Zhou D, et al. Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmun ELISA IgG/IgA assays in a clinical lab. Clinica chimica acta. 2020;510:687-90.
40. Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, et al. Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays. Microbiology Spectrum. 2021;9(1):e00247-21.
41. Ortiz-Dosal A, Loredo-García E, Álvarez-Contreras AG, Núñez-Leyva JM, Ortiz-Dosal LC, Kolosovas-Machuca ES. Determination of the Immunoglobulin G Spectrum by Surface-Enhanced Raman Spectroscopy Using Quasispherical Gold Nanoparticles. Journal of Nanomaterials. 2021;2021.
42. Initiative C-HG. The COVID-19 host genetics initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. European Journal of Human Genetics. 2020;28(6):715.
43. Velikova T, Georgiev T. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatology international. 2021;41(3):509-18.
44. Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Science of the Total Environment. 2020;730:138996.
45. Lee SW, Moon J-Y, Lee S-K, Lee H, Moon S, Chung SJ, et al. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions. Frontiers in immunology. 2021;12:779212-.
46. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight US locations, December 2020–March 2021. Morbidity and Mortality Weekly Report. 2021;70(13):495.
47. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nature Reviews Immunology. 2021;21(10):626-36.
48. Sultana J, Mazzaglia G, Luxi N, Cancellieri A, Capuano A, Ferrajolo C, et al. Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. Expert review of vaccines. 2020;19(10):919-36.
49. Eyre DW, Lumley SF, Wei J, Cox S, James T, Justice A, et al. Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status. Clinical Microbiology and Infection. 2021;27(10):1516. e7-. e14.
50. Whitaker HJ, Tsang RSM, Byford R, Andrews NJ, Sherlock J, Sebastian Pillai P, et al. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. J Infect. 2022;84(5):675-83.
51. Kaura A, Trickey A, Shah AS, Benedetto U, Glampson B, Mulla A, et al. Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum. EClinicalMedicine. 2022;46:101344.
52. Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. bmj. 2021;373.
53. Ranzani OT, Hitchings MD, Dorion M, D’Agostini TL, de Paula RC, de Paula OFP, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. bmj. 2021;374.
54. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. bmj. 2022;376.
55. Cucunawangsih C, Wijaya RS, Lugito NPH, Suriapranata I. Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine. Int J Infect Dis. 2022;118:116-8.
56. Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: A review. Vaccine. 2018;36(36):5350-7.
57. Kaura A, Trickey A, Shah ASV, Benedetto U, Glampson B, Mulla A, et al. Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum. eClinicalMedicine. 2022;46:101344.
Published
2022-11-21
How to Cite
Jariyapongpaiboon, Y., sirijanchune, piyaporn, Khusuwan, S., & Chueamuangphan, N. (2022). Antibody response after the third dose of Covid-19 booster vaccination in healthcare workers. The Clinical Academia, 46(3), 68-77. Retrieved from https://journal.axiomlaboratory.com/index.php/theclinicalacademia/article/view/33
Section
Articles
